BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30701541)

  • 1. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Barth MJ; Minard-Colin V
    Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
    Galardy PJ; Bedekovics T; Hermiston ML
    Br J Haematol; 2016 May; 173(4):625-36. PubMed ID: 27019108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in childhood non-Hodgkin's lymphomas.
    Dokmanovic L
    Biomark Med; 2013 Oct; 7(5):791-801. PubMed ID: 24044571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum.
    Sandlund JT; Martin MG
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):589-597. PubMed ID: 27913533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
    Rosenthal A
    Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies.
    Egan G; Goldman S; Alexander S
    Br J Haematol; 2019 Jun; 185(6):1071-1085. PubMed ID: 30613948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
    Metzger ML; Mauz-Körholz C
    Br J Haematol; 2019 Jun; 185(6):1142-1157. PubMed ID: 30729493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.
    Larose H; Burke GAA; Lowe EJ; Turner SD
    Br J Haematol; 2019 Jun; 185(6):1043-1054. PubMed ID: 30681723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma study group of JCOG.
    Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
    Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.
    Cairo MS; Pinkerton R
    Br J Haematol; 2016 May; 173(4):507-30. PubMed ID: 27133800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
    Sujobert P; Rioufol C; Salles GA
    Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Hodgkin lymphoma in children: a 20-year population-based epidemiologic study in western Sweden.
    Samuelsson BO; Ridell B; Röckert L; Gustafsson G; Márky I
    J Pediatr Hematol Oncol; 1999; 21(2):103-10. PubMed ID: 10206455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
    El-Mallawany NK; Cairo MS
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):113-23. PubMed ID: 25774481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.